AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer
Pharmaceutical Technology
JUNE 1, 2023
Safety and tolerability were in line with that observed in prior trials and the known profiles of the medicines. Dave Fredrickson, executive vice president of AstraZeneca’s oncology business unit, claimed that these results can satisfy a critical unmet need for new BRCAm mCRPC treatments.
Let's personalize your content